Posaconazole (Noxafil)

Antifungal prophylaxis used during Venetoclax-based chemotherapy for Aml. Patient referred to this medication as "PCOSA" in a clinical note (2026-04-15).

Clinical Context

Posaconazole is standard antifungal prophylaxis for patients on venetoclax-based regimens who are at risk of invasive fungal infections due to prolonged neutropenia. It is also a strong CYP3A4 inhibitor, which has a clinically significant interaction with venetoclax.

Venetoclax Dose Reduction Strategy

Per the patient's report (2026-04-15): "PCOSA when on VEN so decrease dose of VEN — in India they use pharmacodynamics to decrease cost."

When posaconazole is co-administered with venetoclax, the venetoclax dose must be reduced (typically from 400 mg to 50–100 mg daily) due to the strong CYP3A4 inhibition by posaconazole, which dramatically increases venetoclax plasma levels. This is a well-established pharmacokinetic interaction per the venetoclax prescribing information.

In Indian oncology practice, this interaction is intentionally leveraged as a cost-reduction strategy: posaconazole (needed anyway for antifungal prophylaxis) allows a much lower dose of venetoclax to achieve equivalent drug exposure, significantly reducing the cost of treatment. Venetoclax is an expensive medication, and the dose reduction from 400 mg to 50–100 mg can reduce venetoclax cost by 75–87%.

Drug Interactions

Dose

Dose not documented. Typical prophylactic dosing: 300 mg PO BID on Day 1, then 300 mg PO daily. Prescription documents needed to confirm actual dosing.

Monitoring

• Hepatic function (LFTs)
• QTc prolongation risk
• Drug levels if available

Exact dose and frequency are not available. Prescription records should be obtained and ingested.